- Trials with a EudraCT protocol (267)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18)
267 result(s) found for: 821.
Displaying page 1 of 14.
EudraCT Number: 2013-001483-39 | Sponsor Protocol Number: IstitutoOncologicoVeneto | Start Date*: 2014-03-06 |
Sponsor Name:Istituto Oncologico Veneto | ||
Full Title: XELODA metronomic IN PATIENTS WITH advanced hepatocellular carcinoma AND FUNCTIONALITY 'LIVER CHILD-PUGH B | ||
Medical condition: PATIENTS WITH advanced hepatocellular carcinoma AND FUNCTIONALITY 'LIVER CHILD-PUGH B | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019864-36 | Sponsor Protocol Number: PML-DOC-1003 | Start Date*: 2010-08-02 |
Sponsor Name:University Hospital of Antwerp, Department of Respiratory Medicine | ||
Full Title: Open-label, prospective exploratory study to assess the effects of formoterol and beclometasone dipropionate combination therapy on central and peripheral airway dimensions in COPD patients. | ||
Medical condition: COPD (chronic obstructive pulmonary disease) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016502-16 | Sponsor Protocol Number: PML_DOC_0905_/_ISSSYMB0020 | Start Date*: 2009-12-02 |
Sponsor Name:University Hospital Antwerp : Department Respiratory Medicine | ||
Full Title: A randomized, double-blind, placebo-controlled, two way cross-over study to assess the particle deposition and acute effects of formoterol and budesonide combination therapy (Symbicort® forte Turbo... | ||
Medical condition: COPD | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003249-16 | Sponsor Protocol Number: PML_DOC_1102 | Start Date*: 2012-01-06 | |||||||||||
Sponsor Name:University Hospital of Antwerp | |||||||||||||
Full Title: OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN AS... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003722-41 | Sponsor Protocol Number: IOV–GB–1-2014-REGOMA | Start Date*: 2015-04-24 | |||||||||||
Sponsor Name:Istituto Oncologico Veneto – IOV‐IRCCS | |||||||||||||
Full Title: Regorafenib in relapsed glioblastoma. REGOMA study Randomized, controlled open‐label phase II clinical trial | |||||||||||||
Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004125-23 | Sponsor Protocol Number: CCRG19-002 | Start Date*: 2021-05-10 | |||||||||||||||||||||
Sponsor Name:Antwerp University Hospital | |||||||||||||||||||||||
Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma | |||||||||||||||||||||||
Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004124-42 | Sponsor Protocol Number: CCRG19-001 | Start Date*: 2023-04-18 | |||||||||||||||||||||
Sponsor Name:Antwerp University Hopsital | |||||||||||||||||||||||
Full Title: First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients | |||||||||||||||||||||||
Medical condition: histologically or cytologically confirmed solid tumor of the pancreas, esophagus, liver or ovaries that is advanced, recurrent or progressing after at least first-line anti-cancer treatment, or fo... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004877-15 | Sponsor Protocol Number: OPM-RADFORMIN-1801 | Start Date*: 2018-06-11 | |||||||||||
Sponsor Name:Antwerp University Hospital, Department Thoracic Oncology | |||||||||||||
Full Title: Randomised phase II trial of definitive radiotherapy with or without metformin in patients with inoperable stage III non-small cell lung cancer | |||||||||||||
Medical condition: Stage III non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004955-19 | Sponsor Protocol Number: PARIDA-01/2013 | Start Date*: 2014-09-03 | |||||||||||
Sponsor Name:Azienda Ospedaliera di Padova | |||||||||||||
Full Title: PARACETAMOL VERSUS IBUPROFEN FOR PATENT DUCTUS ARTERIOSUS TREATMENT IN PRETERM INFANTS. | |||||||||||||
Medical condition: patent ductus arteriosus hemodynamically important | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004865-11 | Sponsor Protocol Number: IV-FLEC | Start Date*: 2022-03-21 |
Sponsor Name:Win Medica Pharmaceuticals S.A. | ||
Full Title: Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of recent onset atrial fibrillation – a randomized, prospecti... | ||
Medical condition: Restoration of sinus rhythm in patients with recent AF onset | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001926-25 | Sponsor Protocol Number: B300201316844 | Start Date*: 2013-09-23 |
Sponsor Name:Universitair Ziekenhuis Antwerpen | ||
Full Title: Sugammadex and the diaphragm: recovery of diaphragmatic function and neuromuscular blockade | ||
Medical condition: Residual neuromuscular blockade and diphragm fatigue | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001098-15 | Sponsor Protocol Number: CCRG14-001 | Start Date*: 2015-10-13 | ||||||||||||||||
Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
Full Title: Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma | ||||||||||||||||||
Medical condition: Newly diagnosed glioblastoma (WHO grade IV) in adults, treated with surgical resection and chemoradiation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004153-24 | Sponsor Protocol Number: CRAD001JIT36T | Start Date*: 2014-05-25 | |||||||||||
Sponsor Name:Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche | |||||||||||||
Full Title: MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control ... | |||||||||||||
Medical condition: HR+ / HER2 negative metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006833-29 | Sponsor Protocol Number: BPS-MR-PAH-202Amendment1Ireland | Start Date*: 2009-06-29 | |||||||||||
Sponsor Name:Lung LLC | |||||||||||||
Full Title: An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001494-91 | Sponsor Protocol Number: CCRG12-001 | Start Date*: 2012-10-11 | ||||||||||||||||
Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
Full Title: Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in adult patients with acute myeloid leukemia: a multicenter randomized phase II trial | ||||||||||||||||||
Medical condition: Adult patients with acute myeloid leukemia in complete remission | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003247-70 | Sponsor Protocol Number: UZAPED1 | Start Date*: 2007-10-29 | |||||||||||
Sponsor Name:Belgian Study Group for Pediatric Endocrinology | |||||||||||||
Full Title: Efficacy and safety of a 4 year combination therapy of growth hormone and gonadotropin- releasing hormone agonist in children with a short predicted height. | |||||||||||||
Medical condition: predicted short stature | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003229-31 | Sponsor Protocol Number: CCRG21-001 | Start Date*: 2022-12-05 | ||||||||||||||||
Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
Full Title: Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma | ||||||||||||||||||
Medical condition: Malignant pleural mesothelioma, epithelioid subtype (stage I-IV) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000543-33 | Sponsor Protocol Number: PANIB20140110 | Start Date*: 2014-11-20 | |||||||||||
Sponsor Name:Antwerp University Hospital | |||||||||||||
Full Title: An open-label, randomized, controlled, multi-center, Phase II trial comparing Panitumumab versus Bevacizumab in combination with oxaliplatin - 5 FU (FOLFOX) first-line treatment according Ras ... | |||||||||||||
Medical condition: metastatic unresectable colorectal cancer (mCRC) . | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002684-25 | Sponsor Protocol Number: BSGPE2 | Start Date*: 2012-08-06 | |||||||||||
Sponsor Name:Antwerp University Hospital | |||||||||||||
Full Title: Efficacy and safety of a 4 year pubertal therapy with growth hormone (somatropine Omnitrope) or an aromatase inhibitor (letrozole Femara) or the combination of both in boys with a short predicted h... | |||||||||||||
Medical condition: boys with idiopathic short adult stature defined as a predicted adult height below or equal to 164.0 cm ( -2.5 SDS) without a known cause | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004148-23 | Sponsor Protocol Number: 1218.22 | Start Date*: 2013-10-04 |
Sponsor Name:Boehringer Ingelheim International GmbH | ||
Full Title: A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients... | ||
Medical condition: Diabetes Mellitus type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Completed) GB (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) PL (Completed) BG (Completed) HR (Completed) DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
